Back to Search
ANDREW MILLER, DDS,MD
DDS,MD
Oral & Maxillofacial Surgery (D.M.D.)
NPI: 1699822403IndividualAccepts Medicare
Specialties, Licenses & Credentials
Oral & Maxillofacial Surgery (D.M.D.)Primary
Oral & Maxillofacial Surgery
Code: 204E00000X
70622-20(WI)
CMS Specialties
PrimaryORAL SURGERY
Additional
MAXILLOFACIAL SURGERY
Education
VANDERBILT UNIVERSITY SCHOOL OF MEDICINE
Class of 2008
Clinical Trials (4)
4
Linked Trials
0
Recruiting
4
With Results
A Study of Infliximab for Treatment Resistant Major Depression
NCT00463580COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
NCT04352101COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation
NCT02796755COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment
NCT00352885COMPLETEDPHASE4STUDY_CHAIR
Research & Publications (20)
Antidepressants for the treatment of depression in people with cancer.
PMID 36999619·Cochrane Database Syst Rev·2023
6-review
Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation.
PMID 25529904·Brain Behav Immun·2015
2-rct
A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.
PMID 22945416·JAMA Psychiatry·2013
4-observational
Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression.
PMID 23624296·Brain Behav Immun·2013
2-rct
The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: preliminary findings.
PMID 23575741·Neuropsychopharmacology·2013
2-rct
Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine.
PMID 22353759·Neuropsychopharmacology·2012
4-observational
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
PMID 19255312·J Clin Oncol·2009
3-trial
Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.
PMID 18793712·Brain Behav Immun·2009
7-preclinical
Elucidating the consequences of chronic stress on immune regulation and behavior in rheumatoid arthritis.
PMID 17920242·Brain Behav Immun·2008
6-review
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
PMID 18827613·J Thorac Oncol·2008
3-trial
Polar body emission requires a RhoA contractile ring and Cdc42-mediated membrane protrusion.
PMID 18804436·Dev Cell·2008
7-preclinical
Inflammation versus glucocorticoids as purveyors of pathology during stress: have we reached the tipping point?
PMID 18675617·Biol Psychiatry·2008
8-other
Control of the cytokinetic apparatus by flux of the Rho GTPases.
PMID 18481962·Biochem Soc Trans·2008
7-preclinical
Impact of musculoskeletal disease on quality of life in long-standing acromegaly.
PMID 18426816·Eur J Endocrinol·2008
8-other
Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer.
PMID 18281672·J Clin Oncol·2008
6-review
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
PMID 17607121·J Thorac Oncol·2007
3-trial
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
PMID 17634483·J Clin Oncol·2007
3-trial
Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer.
PMID 17409967·J Thorac Oncol·2006
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1000 N OAK AVE
MARSHFIELD, WI 54449 - Phone
- (715) 387-5511
Quick Facts
- NPI
- 1699822403
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 18
- Clinical Trials
- 4
- Publications
- 20
Are you this provider?
Claim Your Profile